[ 对成人急性髓系白血病FAB M2亚型患者的预后意义]

[Prognostic Significance of in Adult Acute Myeloid Leukemia Patients with FAB Subtype M2].

作者信息

Liu Yu, Liu Ya-Jun, Yang Lu, Zhang Yu, Zhang Dan-Feng, Jiang Zhong-Xing, Wang Chong, Liu Yan-Fang, Wang Shu-Juan

机构信息

Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.

Department of Orthopaedics, Brown University, Warren Alpert Medical School/Rhode Island Hospital, Rhode Island, the United States, Providence, RI 02903.

出版信息

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Feb;31(1):64-70. doi: 10.19746/j.cnki.issn.1009-2137.2023.01.010.

DOI:10.19746/j.cnki.issn.1009-2137.2023.01.010

PMID:36765478

Abstract

OBJECTIVE

To study the prognostic value of in acute myeloid leukemia (AML).

METHODS

TaqMan-based reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to detect relative expression of in 214 newly diagnosed adult AML patients and 24 normal controls. Survival functions were estimated using the Kaplan-Meier method and were compared by the Log-rank test. A Cox proportional hazard regression model was used to identify prognostic factors.

RESULTS

The expression level of in adult AML was 34.37%(1.83%-392.63%), which was significantly lower than 92.81%(2.60%-325.84%) of normal controls (<0.001). The prognostic significance of was evaluated in 171 non-acute promyelocytic leukemia patients with complete clinical information and prognostic data. Survival analysis showed that the expression level of had no significant effect on the prognosis of the whole cohort. However, in AML patients with FAB subtype M2 (AML-M2), the 2-year relapse-free survival (RFS) rate of patients with low expression was 35.4%(95%: 0.107-0.601), which was significantly lower than 79.2%(95%: 0.627-0.957) of patients with high expression (=0.012). Multivariate analysis showed that low expression of was an independent risk factor for RFS of AML-M2 patients (=0.355, 95%: 0.126-0.966, =0.049).

CONCLUSION

In adult AML patients shows low expression. Low expression is an independent risk factor for RFS in M2-AML patients.

摘要

目的

研究[具体内容]在急性髓系白血病（AML）中的预后价值。

方法

采用基于TaqMan的逆转录定量聚合酶链反应（RT-qPCR）检测214例新诊断的成年AML患者和24例正常对照中[具体内容]的相对表达。使用Kaplan-Meier方法估计生存函数，并通过对数秩检验进行比较。采用Cox比例风险回归模型确定预后因素。

结果

成年AML中[具体内容]的表达水平为34.37%（1.83%-392.63%），显著低于正常对照的92.81%（2.60%-325.84%）（<0.001）。在171例具有完整临床信息和预后数据的非急性早幼粒细胞白血病患者中评估了[具体内容]的预后意义。生存分析表明，[具体内容]的表达水平对整个队列的预后无显著影响。然而，在FAB亚型M2（AML-M2）的AML患者中，低[具体内容]表达患者的2年无复发生存（RFS）率为35.4%（95%：0.107-0.601），显著低于高[具体内容]表达患者的79.2%（95%：0.627-0.957）（P=0.012）。多因素分析表明，低[具体内容]表达是AML-M2患者RFS的独立危险因素（P=0.355，95%：0.126-0.966，P=0.049）。